Smartleaf Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.58M Buy
56,738
+8,445
+17% +$225K 0.06% 298
2025
Q4
$1.21M Buy
48,293
+15,605
+48% +$394K 0.05% 345
2025
Q3
$780K Buy
32,688
+13,755
+73% +$340K 0.05% 373
2025
Q2
$458K Sell
18,933
-9,642
-34% -$225K 0.04% 389
2025
Q1
$720K Buy
28,575
+5,086
+22% +$133K 0.07% 286
2024
Q4
$621K Sell
23,489
-952
-4% -$25.8K 0.06% 298
2024
Q3
$711K Buy
24,441
+12,202
+100% +$356K 0.09% 246
2024
Q2
$340K Sell
12,239
-285
-2% -$7.85K 0.06% 298
2024
Q1
$348K Buy
12,524
+5,918
+90% +$164K 0.07% 261
2023
Q4
$186K Buy
+6,606
New +$200K 0.05% 325

Other funds holding PFE

Smartleaf Asset Management's PFE Position: Q1 2026 in Review

Smartleaf Asset Management increased its Pfizer (PFE) stake by 17% in Q1 2026, buying an estimated $225K and bringing the position to 56,738 shares worth $1.58M. The position accounts for 0.06% of the portfolio, ranked #298.

Smartleaf Asset Management first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Smartleaf Asset Management held 56,738 shares of Pfizer worth $1.58M as of Q1 2026.
  • Smartleaf Asset Management bought 8,445 Pfizer shares in Q1 2026, an estimated $225K.
  • Pfizer made up 0.06% of Smartleaf Asset Management's portfolio in Q1 2026, its #298 holding.
  • Smartleaf Asset Management first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.